Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03157830 · ClinicalTrials.gov registry record
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
A clinical trial of Relapsing Remitting Multiple Sclerosis, sponsored by Providence Health & Services.
- Completed
- Registry status
- 43
- Enrollment target
- 5
- Study locations
NCT03157830 is a study of Relapsing Remitting Multiple Sclerosis that has completed, run by Providence Health & Services. The registered enrollment target is 43 participants, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (79% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT03157830, a study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of this study is to assess the efficacy of Ocrelizumab (OCR) in Relapsing Multiple Sclerosis patients who have been previously treated with natalizumab (NTZ) by evaluating relapse rate, progression on MRI and disability progression.
Conditions Studied
Study Locations (5)
Washington
- Kadlec Neuroscience Center - Richland
- Multiple Sclerosis Center, Swedish Neuroscience Institute - Seattle
- Providence Multiple Sclerosis Center - Spokane
New Jersey
- RWJBarnabas Health - Livingston
Oregon
- Providence MS Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2022-06-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03157830
The ClinicalTrials.gov registry entry for NCT03157830 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (79% lower). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT03157830 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Washington, New Jersey, Oregon.
Frequently Asked Questions
What is clinical trial NCT03157830 about?
NCT03157830 is a clinical study titled "Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab". The primary objective of this study is to assess the efficacy of Ocrelizumab (OCR) in Relapsing Multiple Sclerosis patients who have been previously treated with natalizumab (NTZ) by evaluating relapse rate, progression on MRI and disability progression.
What is the current status of trial NCT03157830?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2017-06-01. Estimated completion is 2022-06-06.
What conditions does trial NCT03157830 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
Who is sponsoring clinical trial NCT03157830?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03157830 being conducted?
This trial has 5 study locations across New Jersey, Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
RECRUITING
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.